vs
Side-by-side financial comparison of HeartCore Enterprises, Inc. (HTCR) and Opus Genetics, Inc. (IRD). Click either name above to swap in a different company.
Opus Genetics, Inc. is the larger business by last-quarter revenue ($3.9M vs $3.0M, roughly 1.3× HeartCore Enterprises, Inc.). On growth, Opus Genetics, Inc. posted the faster year-over-year revenue change (-10.2% vs -81.6%). Over the past eight quarters, Opus Genetics, Inc.'s revenue compounded faster (50.3% CAGR vs -5.2%).
HeartCore Enterprises, Inc. is a global SaaS provider specializing in customer experience management, digital transformation solutions, and marketing technology tools. It operates mainly in Japan, Asia-Pacific, and North America, serving small-to-medium businesses and large enterprises with content management systems, marketing automation platforms, and CRM solutions.
Opus Genetics, Inc. is a clinical-stage biotechnology company specializing in the development of targeted gene therapies for inherited retinal diseases. It focuses on addressing unmet medical needs for patients living with rare, vision-threatening ocular conditions, with operations centered on advancing accessible therapeutic candidates for global rare disease patient populations.
HTCR vs IRD — Head-to-Head
Income Statement — Q3 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $3.0M | $3.9M |
| Net Profit | $434.1K | — |
| Gross Margin | 49.1% | — |
| Operating Margin | -0.4% | — |
| Net Margin | 14.5% | — |
| Revenue YoY | -81.6% | -10.2% |
| Net Profit YoY | -96.1% | 53.0% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $3.9M | ||
| Q3 25 | $3.0M | $3.1M | ||
| Q2 25 | $4.7M | $2.9M | ||
| Q1 25 | $3.6M | $4.4M | ||
| Q4 24 | $-2.7M | $4.3M | ||
| Q3 24 | $16.2M | $3.9M | ||
| Q2 24 | $4.1M | $1.1M | ||
| Q1 24 | $5.0M | $1.7M |
| Q4 25 | — | — | ||
| Q3 25 | $434.1K | $-17.5M | ||
| Q2 25 | $1.1M | $-7.4M | ||
| Q1 25 | $-3.1M | $-8.2M | ||
| Q4 24 | $-9.3M | — | ||
| Q3 24 | $11.1M | $-7.5M | ||
| Q2 24 | $-2.0M | $-7.8M | ||
| Q1 24 | $-1.3M | $-7.1M |
| Q4 25 | — | — | ||
| Q3 25 | 49.1% | — | ||
| Q2 25 | 46.7% | — | ||
| Q1 25 | 30.7% | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 86.3% | — | ||
| Q2 24 | 19.8% | — | ||
| Q1 24 | 40.3% | — |
| Q4 25 | — | — | ||
| Q3 25 | -0.4% | -269.9% | ||
| Q2 25 | 2.3% | -309.0% | ||
| Q1 25 | -34.7% | -227.2% | ||
| Q4 24 | 386.5% | — | ||
| Q3 24 | 76.0% | -207.1% | ||
| Q2 24 | -37.1% | -748.9% | ||
| Q1 24 | -13.5% | -450.5% |
| Q4 25 | — | — | ||
| Q3 25 | 14.5% | -566.9% | ||
| Q2 25 | 23.2% | -257.5% | ||
| Q1 25 | -86.1% | -187.5% | ||
| Q4 24 | 346.8% | — | ||
| Q3 24 | 68.1% | -194.6% | ||
| Q2 24 | -48.0% | -698.3% | ||
| Q1 24 | -26.4% | -415.3% |
| Q4 25 | — | — | ||
| Q3 25 | $0.02 | $-0.25 | ||
| Q2 25 | $0.04 | $-0.12 | ||
| Q1 25 | $-0.14 | $-0.24 | ||
| Q4 24 | $-0.45 | — | ||
| Q3 24 | $0.53 | $-0.29 | ||
| Q2 24 | $-0.09 | $-0.30 | ||
| Q1 24 | $-0.06 | $-0.29 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $4.4M | $45.1M |
| Total DebtLower is stronger | $510.9K | — |
| Stockholders' EquityBook value | $5.2M | $15.3M |
| Total Assets | $13.3M | $50.2M |
| Debt / EquityLower = less leverage | 0.10× | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $45.1M | ||
| Q3 25 | $4.4M | $30.8M | ||
| Q2 25 | $2.5M | $32.4M | ||
| Q1 25 | $2.3M | $41.8M | ||
| Q4 24 | $6.5M | $30.3M | ||
| Q3 24 | $8.6M | $36.6M | ||
| Q2 24 | $4.2M | $41.4M | ||
| Q1 24 | $1.6M | $47.2M |
| Q4 25 | — | — | ||
| Q3 25 | $510.9K | — | ||
| Q2 25 | $1.5M | — | ||
| Q1 25 | $1.5M | — | ||
| Q4 24 | $545.1K | — | ||
| Q3 24 | $1.9M | — | ||
| Q2 24 | $1.9M | — | ||
| Q1 24 | $2.0M | — |
| Q4 25 | — | $15.3M | ||
| Q3 25 | $5.2M | $6.0M | ||
| Q2 25 | $4.8M | $17.5M | ||
| Q1 25 | $1.8M | $5.1M | ||
| Q4 24 | $4.7M | $6.7M | ||
| Q3 24 | $12.4M | $34.3M | ||
| Q2 24 | $1.6M | $40.6M | ||
| Q1 24 | $3.9M | $46.1M |
| Q4 25 | — | $50.2M | ||
| Q3 25 | $13.3M | $36.1M | ||
| Q2 25 | $13.5M | $38.7M | ||
| Q1 25 | $10.2M | $48.2M | ||
| Q4 24 | $14.0M | $36.9M | ||
| Q3 24 | $25.5M | $40.4M | ||
| Q2 24 | $24.1M | $44.8M | ||
| Q1 24 | $22.3M | $51.8M |
| Q4 25 | — | — | ||
| Q3 25 | 0.10× | — | ||
| Q2 25 | 0.31× | — | ||
| Q1 25 | 0.84× | — | ||
| Q4 24 | 0.12× | — | ||
| Q3 24 | 0.15× | — | ||
| Q2 24 | 1.20× | — | ||
| Q1 24 | 0.50× | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $-35.3M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $-35.3M | ||
| Q3 25 | — | $-6.2M | ||
| Q2 25 | $-674.1K | $-10.3M | ||
| Q1 25 | $-2.0M | $-9.0M | ||
| Q4 24 | $-1.3M | $-25.6M | ||
| Q3 24 | $-1.8M | $-5.1M | ||
| Q2 24 | $-837.1K | $-7.3M | ||
| Q1 24 | $-898.6K | $-5.7M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.61× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | -0.16× | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
HTCR
| Customised Software Development And Services | $1.7M | 58% |
| Software Related Cost Of Revenues | $1.4M | 46% |
IRD
Segment breakdown not available.
